CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 487 enrolled
Drug / intervention
CP-690,550drug
Likely dose
CP-690,550 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00661661
NCT00661661Phase 3Completed
CompareCT.gov

A Long-term, Open-label Study Of Cp-690,550 to Confirm The Safety Following Long Term Administration Of Cp-690,550 In The Treatment Of Rheumatoid Arthritis

Pfizer·interventional·Posted Apr 18, 2008·Updated May 12, 2015

In Brief

A Phase 3 clinical trial evaluating CP-690,550 for Rheumatoid Arthritis. Completed, enrolled 487 participants across 56 sites.

Detailed Summary

The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Subjects are only eligible for this study after they have completed participation in another "qualifying" study of CP-690,550.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 18, 2008
Enrollment StartApr 1, 2008
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 18.2 years ago

Interventions

CP-690,550drug

5 mg BID up to 10 mg BID until launch